Market Assessment, Psoriasis Moderate to Severe Decision Base US 2015 Report

With the Entry of New Oral and Biological Agents, Where Are the Remaining Areas of Opportunity in an Increasingly Crowded Market?

Affecting more than three million people in the major pharmaceutical markets, moderate to severe psoriasis represents a large market with substantial commercial opportunity. However, competition is set to intensify with the recent launch of the first approved IL-17 inhibitor, secukinumab (Novartis’s Cosentyx), and other highly efficacious biologics in the late-stage pipeline. These agents’ efficacy on more-stringent measures of response (i.e., PASI 90 and PASI 100 response rates) and superior efficacy to current agents in head-to-head studies will significantly raise the bar for psoriasis therapies.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Psoriasis (Moderate to Severe) | Decision Base | US | 2015

Related Market Assessment Reports

Asthma | Unmet Need | Severe Asthma | US/EU | 2021

Asthma – Unmet Need – Detailed, Expanded Analysis – Severe Asthma (US/EU)

Pulmonary Hypertension – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Crohn’s Disease – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Pediatric Crohn’s Disease (US)

Chronic Kidney Disease – Current Treatment – Detailed, Expanded Analysis – Treatment Algorithms – Claims Data Analysis (US)